Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT03764137 | Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer(Panitumumab) | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Jan 31, 2025 |
| clinicaltrials |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors(AcTRESS) | withdrawn | Phase 1 | 0 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease | withdrawn | — | 0 | Ugur Arzu KuluOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | withdrawn | Phase 1 | 0 | GC Cell CorporationINDUSTRY | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT06135545 | Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block | withdrawn | N/A | 0 | Shiyou WeiOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04271436 | Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06537063 | Detection of G-quadruplex DNA Methylation in Cancer | withdrawn | — | 0 | Zhongnan HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | withdrawn | Phase 4 | 0 | Corewell Health EastOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Jan 1, 2025 | clinicaltrials |
| NCT04260230 | Remote Monitoring of Patients at Risk of Sepsis(REACT) | withdrawn | N/A | 0 | The Christie NHS Foundation TrustOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer(OVERPASS) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06331598 | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)(IMperator) | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT05640115 | Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent | withdrawn | Early Phase 1 | 0 | University of ChicagoOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | withdrawn | N/A | 0 | University of VirginiaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | withdrawn | — | 0 | Dr. Tamim NiaziOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02347839 | NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.(NEGOTIATE) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02428764 | Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | withdrawn | — | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 10, 2024 | clinicaltrials |
| NCT03164694 | APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC(APPEAL) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06227897 | Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).(AERESA) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06219733 | Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)(MP-VAC-206) | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722885 | Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System(SBRT_LOV) | withdrawn | — | 0 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | withdrawn | Phase 2 / Phase 3 | 0 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | withdrawn | Phase 1 | 0 | Leland MethenyOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02699229 | Non-linear Multimodal Microendoscopy for Lung Cancer Pathology | withdrawn | — | 0 | University Health Network, TorontoOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT03622528 | Quantitative Lung Cancer Screening | withdrawn | — | 0 | Jessica SierenOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT04160182 | Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04232319 | Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04272294 | Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy | withdrawn | N/A | 0 | University of ArkansasOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients | withdrawn | N/A | 0 | Tel Aviv UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06654258 | Supporting Spiritual Wellbeing in Young Adults With Cancer Using a Digital Health Approach: A Feasibility Study | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Nov 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2025source: clinicaltrials